EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dual ET A ‐ET B receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction

Francesca Lockwood iD, Marianne Lachaux, Najah Harouki, Matthieu Soulié, Lionel Nicol, Sylvanie Renet, Anaïs Dumesnil, Magali Vercauteren, Jeremy Bellien, Marc Iglarz, Vincent Richard, Paul Mulder

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Francesca Lockwood und 11 weiteren Autor:innen. Beteiligte Einrichtung: Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France. Hauptthemen laut MEDLINE: Metabolic Syndrome, Heart Failure, Stroke Volume, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Actelion Pharmaceuticals, European Union and the Région Normandie, WinningNormandy Marie Skłodowska-Curie post-doc fellowship H2020-MSCA-COFUND-2020, Marie Skłodowska-Curie grant agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic syndrome (MetS) is a multifaceted disease associated with heart failure (HF), which affects the vascular system. The endothelin (ET) system is a key player in MetS and HF; therefore, targets for ET receptors are of therapeutic interest.

Objectives

This study sought to evaluate the effects of macitentan, a dual endothelin receptor antagonist (ERA), in a rat model of MetS‐induced heart failure with preserved ejection fraction (HFpEF).

Methods

We assessed in 12‐week‐old Zucker fa/fa rats the effects of macitentan (10 mg/kg/day as a food additive for short‐term/7‐ or long‐term/90‐day treatment) on right ventricular (RV) and left ventricular (LV) function/remodelling (MRI), RV and LV haemodynamics (catheterization) and RV and LV coronary function (myograph).

Results

After 7‐ and 90‐days, untreated Zucker fa/fa rats presented isolated LV diastolic dysfunction (illustrated by elevated LV end‐diastolic pressure [EDP] and LV end‐diastolic pressure‐volume relationship [EDPVR] without changes in LV EDPVR). This was associated with increased collagen deposition and impaired endothelium‐dependent coronary artery relaxation. Macitentan 7‐ and 90‐day treatment significantly decreased blood pressure and prevented LV, RV and coronary dysfunctions and long‐term treatment reduced LV collagen density. Moreover, 7‐ and 90‐day macitentan treatment significantly reduced cardiac inflammation and reactive oxygen species (ROS) production.

Conclusions

Dual ERA macitentan improved both LV and RV diastolic dysfunction. This was associated with improved coronary vasodilation, diminished cardiac oxidative stress and improved blood composition. These results suggest that antagonizing the ET system with macitentan is a promising approach to treat HFpEF and its complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeHeart FailureStroke VolumePyrimidinesEndothelin A Receptor AntagonistsSulfonamidesEndothelin B Receptor AntagonistsAnimalsRats, ZuckerRatsMaleDisease Models, AnimalVentricular Function, LeftVentricular RemodelingVentricular Dysfunction, Left

Stichwörter der Autor:innen

cardiac remodellingendothelinheart failuremetabolic syndrome

Substanzen

macitentanPyrimidinesEndothelin A Receptor AntagonistsSulfonamidesEndothelin B Receptor Antagonists

Autor:innen und Institutionen

  • Univ Rouen Normandie, INSERM U1096, EnVI, Rouen, France.
  • Institute for Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.
  • Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland.

ORCID-Profile: Francesca Lockwood

Förderung

  • Actelion Pharmaceuticals
  • European Union and the Région Normandie
  • WinningNormandy Marie Skłodowska-Curie post-doc fellowship H2020-MSCA-COFUND-2020, Marie Skłodowska-Curie grant agreement
  • European Fibro-Targets Project
  • Actelion Pharmaceuticals Ltd.
  • European Union
  • Région Normandie
  • FP7-funded COST ADMIRE network

Zitieren

APA

Lockwood, F., Lachaux, M., Harouki, N., Soulié, M., Nicol, L., Renet, S., Dumesnil, A., Vercauteren, M., Bellien, J., Iglarz, M., Richard, V., & Mulder, P. (2025). Dual ET A ‐ET B receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70006

Vancouver

Lockwood F, Lachaux M, Harouki N, Soulié M, Nicol L, Renet S, et al. Dual ET A ‐ET B receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70006

BibTeX
@article{Lockwood2025,
  author = {Lockwood, Francesca and Lachaux, Marianne and Harouki, Najah and Soulié, Matthieu and Nicol, Lionel and Renet, Sylvanie and Dumesnil, Anaïs and Vercauteren, Magali and Bellien, Jeremy and Iglarz, Marc and Richard, Vincent and Mulder, Paul},
  title = {Dual ET A ‐ET B receptor antagonism improves metabolic syndrome‐induced heart failure with preserved ejection fraction},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70006}
}
Kostenlos starten →